Ilia I. Ouspenski

Array ( [id] => 16468207 [patent_doc_number] => 20200369744 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => BSL2v2c2-Ig POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 16/778159 [patent_app_country] => US [patent_app_date] => 2020-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70101 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16778159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18717878 [patent_doc_number] => 11795209 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-24 [patent_title] => PVRIG polypeptides and methods of treatment [patent_app_type] => utility [patent_app_number] => 16/775133 [patent_app_country] => US [patent_app_date] => 2020-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 223 [patent_figures_cnt] => 345 [patent_no_of_words] => 58474 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16775133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16807915 [patent_doc_number] => 20210130468 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => Antigen Binding Proteins that Bind PD-1 [patent_app_type] => utility [patent_app_number] => 16/742712 [patent_app_country] => US [patent_app_date] => 2020-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23922 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16742712 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18341911 [patent_doc_number] => 11639385 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-02 [patent_title] => Anti-PD-1 antibodies [patent_app_type] => utility [patent_app_number] => 16/728653 [patent_app_country] => US [patent_app_date] => 2019-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 37 [patent_no_of_words] => 18519 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16728653 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18355074 [patent_doc_number] => 11643464 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-09 [patent_title] => Reducing systemic regulatory T cell levels or activity for treatment of a retinal degeneration disorder [patent_app_type] => utility [patent_app_number] => 16/728587 [patent_app_country] => US [patent_app_date] => 2019-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 76 [patent_no_of_words] => 28533 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16728587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15866303 [patent_doc_number] => 20200140555 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS [patent_app_type] => utility [patent_app_number] => 16/728642 [patent_app_country] => US [patent_app_date] => 2019-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34046 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 177 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16728642 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19931740 [patent_doc_number] => 12304937 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-20 [patent_title] => Leptin immunogens, hybridoma cells, monoclonal antibodies, polyclonal antibodies and use thereof [patent_app_type] => utility [patent_app_number] => 17/424484 [patent_app_country] => US [patent_app_date] => 2019-12-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 808 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17424484 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18518531 [patent_doc_number] => 11708412 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-25 [patent_title] => Methods for treating hematologic cancers [patent_app_type] => utility [patent_app_number] => 16/724759 [patent_app_country] => US [patent_app_date] => 2019-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 23 [patent_no_of_words] => 40119 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16724759 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16900797 [patent_doc_number] => 20210179713 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => ANTI-PD-1 ANTIBODIES, ACTIVATABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/725587 [patent_app_country] => US [patent_app_date] => 2019-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 118076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16725587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16206552 [patent_doc_number] => 20200239542 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => B7-H5, A Costimulatory Polypeptide [patent_app_type] => utility [patent_app_number] => 16/707719 [patent_app_country] => US [patent_app_date] => 2019-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10850 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16707719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15678403 [patent_doc_number] => 20200093865 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/701818 [patent_app_country] => US [patent_app_date] => 2019-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69312 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16701818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020607 [patent_doc_number] => 20220372106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => CD86 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/298506 [patent_app_country] => US [patent_app_date] => 2019-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79249 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -171 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17298506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16156605 [patent_doc_number] => 20200216535 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => ANTI-PD1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS [patent_app_type] => utility [patent_app_number] => 16/684237 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16072 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16684237 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17312838 [patent_doc_number] => 20210401886 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => METHODS AND MATERIALS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/288212 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7611 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288212 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18619167 [patent_doc_number] => 11752189 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-12 [patent_title] => Vista antagonist and methods of use [patent_app_type] => utility [patent_app_number] => 16/669552 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 16853 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16669552 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15496329 [patent_doc_number] => 20200048353 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => ANTI-B7-H3 ANTIBODIES AND DIAGNOSTIC USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/665359 [patent_app_country] => US [patent_app_date] => 2019-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19126 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16665359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17314517 [patent_doc_number] => 20210403565 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/288187 [patent_app_country] => US [patent_app_date] => 2019-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39225 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288187 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17776599 [patent_doc_number] => 20220242948 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => ANTI-L1CAM ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME [patent_app_type] => utility [patent_app_number] => 17/285184 [patent_app_country] => US [patent_app_date] => 2019-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23764 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285184 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19948393 [patent_doc_number] => 12319740 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-03 [patent_title] => Methods for production of tissue resident memory-like T cells and use thereof [patent_app_type] => utility [patent_app_number] => 17/286086 [patent_app_country] => US [patent_app_date] => 2019-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 23 [patent_no_of_words] => 11089 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17286086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15432485 [patent_doc_number] => 20200030425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/601231 [patent_app_country] => US [patent_app_date] => 2019-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74573 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16601231 [rel_patent_id] =>[rel_patent_doc_number] =>)